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Introduction
In 2015, an estimated 231,840 new cases of invasive breast 
cancer was diagnosed among women, with approximately 
40,000 women expected to have died from their disease 
[1]. Of the total number of new cases, an estimated 1.8% 
will be in patients under the age of 35. Of the estimated 
deaths in 2015, approximately 1.0% was estimated in these 
young women. Cancer is the leading cause of death in 
women 20–39 years of age, with breast cancer being the 
most common cancer type in this age group [2]. Although 
the exact definition of “young” women with breast cancer 
is debatable as evidenced by the variability in defining 
this population in breast cancer reviews, majority of series 
suggest a worse prognosis in young women compared 
with older women [3].
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Abstract
Younger age diagnosis of breast cancer is a predictor of adverse outcome. Here, 
we evaluate prognostic factors in young women with locally advanced breast 
cancer (LABC). We present a retrospective review of 104 patients younger than 
40 years with LABC treated with surgery, radiotherapy (RT), and chemotherapy 
from 2003 to 2014. Patient- , tumor- , and treatment- related factors important 
for overall survival (OS), local/regional recurrence (LRR), distant metastasis 
(DM), and recurrence- free survival (RFS) were evaluated. Mean age at diagnosis 
was 34 years (23–39 years) with a median follow- up of 47 months (8–138 months). 
Breast- conserving surgery was performed in 27%. Axillary lymph node dissec-
tion was performed in 85%. Sixty percent of patients received neoadjuvant 
chemotherapy with 19% achieving pathologic complete response (pCR), and 
61% downstaged. Lymph node positivity was present in 91% and lymphovascular 
space invasion (LVSI) in 35%. Thirty- two percent of patients had triple negative 
tumors (TN, ER- /PR- /HER2 nonamplified). Four- year OS and RFS was 84% 
and 71%, respectively. Factors associated with worse OS on multivariate analysis 
include TN status, LVSI, and number of positive lymph nodes. LVSI was also 
associated with DM and LRR, as well as worse RFS. Downstaging was associated 
with improved 4 year RFS in patients receiving neoadjuvant chemotherapy (74% 
vs. 38%, P = 0.002). With high risks of recurrence and inferior OS compared 
to older women, breast cancer in young women can be difficult to treat. Among 
additional factors, presence of LVSI and lack of downstaging portends a 
 particularly worse prognosis.
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Most published series on breast cancer in young women 
have included both early- stage disease with the more 
 aggressive locally advanced breast cancer (LABC). LABC 
refers to most advanced- stage nonmetastatic breast tumors 
[4] and may be operationally defined as tumors greater 
than 5 cm or that involve the skin or chest wall, or 
involvement of lymph nodes. Thus, all stage IIIA- C and 
stage IIB (T2N1, T3N0) disease would be classified as 
LABC. Treatment of LABC requires a multimodal  approach 
with a combination of systemic chemotherapy, surgery, 
and radiation therapy in order to achieve optimal chance 
of cure. Young women with breast cancer are more likely 
to have larger tumors and nodal involvement [5, 6]. 
Several factors have been linked to the poor prognosis 
associated with breast cancer in young women, including 
large tumor size, higher tumor grade, mitotic rate, lym-
phovascular space invasion (LVSI), increased expression 
of HER2, and lower estrogen and progesterone receptor 
expression [7, 8].
Here, we present our institutional experience in women 
younger than 40 years of age diagnosed with LABC (T3- 4N0, 
T1- 4N1) who had radiation as a component of their treat-
ment. Young women with LABC are invariably treated 
with surgery, radiation therapy, chemotherapy and/or 
hormonal therapy. These patients are often faced with 
personal, family, professional, and quality- of- life issues 
that further complicate treatment decision- making. Many 
have argued for more tailored therapies in this population 
arguing that reliance on information from older women 
will not be adequate to treat younger patients [9]. Few 
studies have exclusively evaluated factors important for 
survival in young women diagnosed with LABC. We pre-
sent one of the few series exclusively addressing patient- , 
tumor- , and treatment- related factors important for overall 
survival (OS) and recurrence- free survival (RFS) in this 
young population with locally advanced disease.
Materials and Methods
The source for this analysis was de- identified data from 
an IRB- approved prospective registry. From this registry, 
we conducted a retrospective chart- based review of 104 
breast cancer patients less than 40 years of age treated 
with a combination of surgery, comprehensive radiotherapy 
(RT) +/− chemotherapy from 2003 to 2014. Patient- , 
tumor- , and treatment- specific factors that were hypoth-
esized to predict OS, local/regional recurrence (LRR), 
distant metastasis (DM), or RFS were evaluated (Table 1). 
RFS was defined as freedom from local/regional and distant 
failure.
Only patients with LABC were included. LABC was 
operationally defined as any node positive or T3- 4N0 
cancer. For patients receiving neoadjuvant therapy, 
pretreatment clinical stage was utilized. All patients clini-
cally node negative had an axillary ultrasound (US) and 
subsequent fine needle aspiration (FNA) or sentinel lymph 
node biopsy performed for suspicious nodes. All clinically 
node positive patients had FNA confirmation. T3N0 
 patients who received mastectomy followed by postmas-
tectomy radiation treatment had one or more of high 
risk features warranting radiation treatment, which included 
LVSI, close (<2 mm) or positive margin, and/or triple 
negative (TN) receptor status.
Patient- specific factors recorded include: age at diagnosis, 
race, BRCA1 and BRCA2 gene mutation status, and family 
history of breast cancer. Tumor- specific factors recorded 
Table 1. Patient and treatment characteristics (n = 104).
N (%)
Mean age at diagnosis (years) 34.5 (23–39)
Race
 Caucasian 64 61.5
 African American 31 29.8
 Other 9 8.6
Family history
 Any positive family history 45 43.3
 1st degree relative 18/45 40.0
 2nd/3rd degree relative 25/45 55.6
 Distant relative (>3rd degree) 2/45 4.4
BRCA1/BRCA 2 gene testing
 Testing performed 57 54.8
 Mutation identified 10 18.5
 No mutation identified 44 77.2
 Variant (VUS) identified 3 5.6
 No testing performed 47 45.2
Surgery
 BCT 28 26.9
 Unilateral Mastectomy 28 26.9
 Bilateral Mastectomy 48 46.2
 Positive/Close Margin 17 16.4
 ALND 88 84.6
Chemotherapy
 Neoadjuvant only 62 59.6
 Neoadjuvant+adjuvant 26 25.0
 Pathologic CR 12/62 19.4
 Downstaged 38/62 61.3
 Adjuvant only 34 32.7
Hormonal therapy
 Neoadjuvant 6 5.8
 Adjuvant 53 51.0
Radiation therapy
 Median dose (cGy) 5040
 Boost received 53 51.0
 Comprehensive RT 99 95.2
 Conventional radiation 41 39.4
 Helical IMRT 12 11.5
 Nonhelical IMRT 51 49.0
BCT, breast conserving therapy; IMRT, intensity modulated radiation 
therapy; ALND, axillary lymph node dissection; CR, complete response; 
VUS, variant of unknown significance.
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include biomarker status (estrogen receptor (ER), proges-
terone receptor (PR), and HER2), multifocality, tumor 
size, number of lymph nodes involved with disease (LN), 
extranodal extension (ENE), perineural invasion (PNI), 
and LVSI. LVSI was documented as either present or 
absent. LVSI was not consistently noted as extensive or 
focal in pathology reports. Treatment- specific factors 
 recorded include type of surgery (breast conserving surgery 
versus mastectomy, type of axillary surgery), type of neo-
adjuvant and/or adjuvant systemic therapy, achievement 
of pathologic complete response (pCR), downstaging, 
radiation technique, dose, and whether a boost to the 
scar was given. Downstaging was defined as any decrease 
in T stage or N stage after neoadjuvant therapy. Patients 
with a decrease in N stage but with an increase in T 
stage (and vice versa) were not classified as downstaged. 
Here pCR was defined as no evidence of in situ or in-
vasive disease after neoadjuvant therapy. All patients re-
ceived comprehensive radiation therapy, which included 
coverage of the breast or chest wall, axillary, supraclavicular 
and internal mammary lymph nodes, except patients with 
T3N0 cancers, who received chest wall radiation alone.
Univariate and multivariate COX regression was per-
formed for OS, LR, DM, and RFS. Survival was assessed 
by Kaplan–Meier analyses utilizing the log- rank test for 
statistical significance. A P- value <0.05 was considered 
statistically significant.
Results
Patient and treatment characteristics
Patient and treatment characteristics are outlined in 
Table 1. Median follow- up time was 47 months (range 
8–138 months). The mean age at diagnosis was 34.5 years 
(range 23–39 years). The majority of patients were 
Caucasian (61.5%) or African American (29.8%). Fifty- 
seven (54.8%) women underwent BRCA1 and BRCA2 
gene testing. Of those tested, 10 women (18.5%) had a 
mutation and three women had a variant of unknown 
clinical significance (VUS). The remaining women tested 
negative. Forty- five patients (43.3%) were documented to 
have any positive family history of breast cancer, with 
18 patients (40.0%) having a documented first degree 
relative and 25 patients (55.6% with a second/third degree 
relative. Twenty- eight patients (26.9%) had breast- 
conserving surgery, 28 patients (26.9%) had a unilateral 
mastectomy, and 48 patients (46.2%) had bilateral mas-
tectomies. Surgery included an axillary lymph node dis-
section in 88 patients (84.6%) with a median number of 
lymph nodes (LN) removed of 15 nodes (interquartile 
range 10–18). The remaining patients had a sentinel lymph 
node excision. A close (<2 mm) or positive margin was 
observed in 17 patients (16.4%), 6 occurring after breast- 
conservation, and the remaining 11 after mastectomy.
A total of 62 patients (59.6%) were administered neo-
adjuvant treatment (chemotherapy with or without tar-
geted therapy) with 12 of these patients (19.4%) showing 
a pathologic complete response to treatment. A total of 
38 of the 62 patients (61.3%) had downstaging of their 
tumors. Thirty- four patients (32.7%) received adjuvant 
chemotherapy alone, whereas 26 patients (25.0%) received 
both neoadjuvant and adjuvant chemotherapy. Various 
chemotherapy regimens were utilized. The most common 
was AC plus or minus T (doxorubicin, cyclophosphamide, 
taxol), FEC (5- fluoruracil, epirubicin, cyclophosphamide), 
and TAC (docetaxel, doxorubicin, cyclophosphamide). 
Select patients also received Avastin (bevacizumab) or 
Herceptin (trastuzumab). A total of six patients (5.9%) 
received neoadjuvant hormonal therapy with an aromatase 
inhibitor or tamoxifen. Fifty- three patients (51.0%) re-
ceived adjuvant hormonal therapy with the most common 
treatment being tamoxifen (n = 40, 74.1%). All patients 
 received adjuvant radiation therapy, which was delivered 
using conventional fields in 41 patients (39.4%), helical 
intensity modulated radiation therapy (H- IMRT) in 12 
patients (11.4%), and nonhelical IMRT in 51 patients 
(49.0%), for which simulation and treatment techniques 
have been described previously [10]. The median dose 
was 5040 cGy. The vast majority of patients received 
comprehensive radiotherapy (n = 99, 95.2%) comprising 
chest wall and regional nodal volume radiation, including 
the internal mammary nodes. The remaining five patients 
received chest wall radiation alone. These patients had 
T3N0 disease. Fifty- three patients (51.0%) received a 
boost, with a median boost dose of 1000 cGy (range 
600–2000 cGy).
Tumor characteristics
Tumor- specific characteristics are outlined in Table 2. The 
mean tumor size was 3.2 cm. Estrogen- receptor positive 
(ER+)/Progesterone- receptor positive (PR+)/HER2 non-
amplified tumors comprised 34%, ER−/PR−/HER2 ampli-
fied tumors 14%, ER+/PR+/HER2 amplified 11% and 
triple negative (TN, ER−/PR−/HER2 nonamplified) 32%. 
The overwhelming majority (96.2%) of tumors were 
 invasive ductal carcinomas (IDC). Majority of tumors were 
grade III (n = 54, 60.7%) or grade II (n = 27, 30.3%). 
Tumors were largely stage II (n = 40, 38.5%) or stage 
III (n = 63, 60.6%). A clinical or pathologic T4 was 
observed in 14 patients (13.5%). The overwhelming 
 majority of patients were LN positive (n = 95, 91.3%). 
Pathologic LN positivity, as assessed by sentinel LN biopsy 
or axillary LN dissection, was present in 76 patients 
(73.1%). Fourteen patients (13.3%) were pathologically 
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LN negative, but were observed to have pathologic LN 
positivity on pretreatment ultrasound FNA. LVSI was seen 
in 36 patients (34.6%), ENE was seen in 27 patients 
(26.0%), and PNI in 6 patients (5.8%). Multifocal disease 
was seen in 20 patients (19.2%).
Events
Table 3 outlines the number of deaths, LRRs, and sites 
of metastatic disease. With a median follow- up of 47 months 
(range 8–138 months), 16 patients (15.4%) died of their 
disease. Twelve patients had local recurrences either 
 in- breast, nodal, or chest wall (11.4%). Only 1 of 12 pa-
tients had an in- breast recurrence only. Four patients had 
nodal and chest wall recurrences. Of the remaining LRRs, 
6 patients had a nodal only recurrence and one patient 
had both a nodal and in- breast recurrence. All 12 of these 
patients eventually developed distant metastatic disease. In 
total, 29 patients (27.9%) had distant recurrences. Some 
patients had more than one site involved. Most common 
sites were brain, bone, lung, and liver. Recurrences were 
treated with chemotherapy only (n = 10), radiotherapy 
only (n = 7), or combination chemotherapy and 
radiotherapy (n = 10). The remaining two patients chose 
pain control with oral analgesics. To date there have been 
no treatment- induced malignancies.
Univariate and multivariate (MVA) Cox regressions were 
performed on the patient- , tumor- , and treatment- specific 
factors (Table 4). Univariate analysis revealed that ER 
positivity was associated with better OS, whereas LVSI, 
number of positive LN, and TN were associated with poor 
OS (P < 0.05). LVSI, number of positive LN, TN status, 
and ER positivity continued to show significance on MVA. 
Similar analyses were performed for local/regional failure- 
free survival (LRRF), DM- free survival, and RFS. Univariate 
analysis for LRRF revealed that African American race, 
number of positive LN, and LVSI were associated with 
poor LRRF, whereas downstaging was  associated with  better 
LRRF (P < 0.05). Number of positive LN, African American 
race, and LVSI remained significant on MVA. Factors as-
sociated with better DM- free survival on univariate analysis 
included downstaging and positive family history of breast 
cancer, whereas LVSI, number of positive LN, and African 
American race were associated with poor DM- free survival 
(P < 0.05). On MVA, LVSI, and downstaging remained 
significant in the model. For RFS, univariate results were 
similar to those in the DM- free survival analysis, with 
LVSI and downstaging remaining significant on MVA 
(P < 0.05). In the patient cohort receiving neoadjuvant 
chemotherapy, LVSI and downstaging were significant fac-
tors for both RFS and DM- free survival. For these patients, 
number of positive LN was also a significant factor for 
LRRF on MVA (P < 0.014).
Table 5 presents survival statistics for OS, RFS, LRRF, 
and DM – free survival. OS at 2 and 4 years was 95% 
and 84%, respectively. RFS at 2 and 4 years was 86% and 
71%, respectively. LRRF at 2 and 4 years was 95% and 
Table 2. Tumor characteristics.
N % (of total)
Mean size (cm) (range in cm) 3.2 (0.2–23.0)
Luminal A (ER+/PR+/HER2 nonamp G1- 2) 20 19.2
Luminal B (ER+/PR+/HER2 nonamp G3) 15 14.4
HER2 (ER−/PR−/HER2 amp) 14 13.5
Luminal- HER2 (ER+/PR+/HER2 amp) 11 10.6




 Invasive ductal 101 96.2
 Invasive lobular 2 1.9
Pathologic grade
 I 8 7.7
 II 27 26.0
 III 53 51.0
Stage (clinical or pathologic)
 II 40 38.5
 III 63 60.6
Clinical or pathologic T4 14 13.5
Lymph node positive 95 91.3
 Path. positive LN (SLNB or AXLND) 76 73.1
 Path. LN negative but LN+ at US 14 13.3





LN, lymph nodes; LVSI, lymphovascular space invasion; ENE, extranodal 
extension; PNI, perineural invasion, ER, estrogen receptor; PR, progrest-
erone receptor; amp, amplified.
Table 3. Summary of events (n = 104 patients).
N (%)
Median follow- up in months (range) 47 (8–138)
Number of deaths 16 15.4
Patients with recurrence 29 27.9
Local/regional recurrences
 Total 12 11.4
 In- breast only 1/12 8.3
 Nodal only 6/12 50.0
 Nodal and in- breast 1/12 8.3
 Nodal and chest wall 4/12 33.3
Patients with distant recurrences
 Total 29 27.9
 Brain 11/29 37.9
 Bone 16/29 55.2
 Lung 12/29 41.3
 Liver 14/29 48.3
 Other 10/29 34.5
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87%, respectively. DM- free survival at 2 and 4 years was 
87% and 72%, respectively. Kaplan–Meier survival curves 
were generated using LVSI status for OS and RFS (Fig. 1A 
and B, respectively). Four- year OS for patients that had 
no evidence of LVSI was 92%, whereas patients with docu-
mented LVSI had a 70% 4- year OS (P = 0.009 on log- 
rank). Similarly, 4- year RFS for patients without LVSI was 
82% as opposed to 52% in patients with LVSI (P = 0.010 
on log- rank). The impact of downstaging on OS and RFS 
in patients receiving neoadjuvant chemotherapy is graphi-
cally represented in Figure 1C and D, respectively. Patients 
successfully downstaged after neoadjuvant chemotherapy 
had improved RFS (P = 0.002), but this did not affect 
their OS (P = 0.117).
Discussion
The present series represents one of the few studies 
 exploring factors associated with survival exclusively in 
young women with LABC. Younger age has been shown 
in multiple retrospective studies and subset analyses of 
larger randomized trials to be a powerful adverse prog-
nostic indicator of LRR and distant metastases in breast 
cancer patients. Many of these randomized trials, however, 
did not have adequate representation of women in this 
young age group. Investigators in the UK recently pub-
lished a prospective study (The Prospective Study of 
Outcomes in Sporadic and Hereditary Breast Cancer – 
POSH)  designed to investigate factors affecting prognosis 
in this group [11]. As one of the few prospective studies, 
POSH highlights the relative poor prognosis in women 
less than 40 years, with an OS at 5 years of 82% and 
DM rate of 24%. Previous retrospective analyses and the 
aforementioned prospective trial in young women have 
included early stage breast cancer patients [8, 12–18]. With 
Table 4. Univariate/multivariate COX regression.
Parameter
Univariate Multivariate
HR 95% CI P- value HR 95% CI P- value
Overall survival
 Triple negative 2.867 1.073–7.662 0.036 6.421 2.009–20.525 0.002
 LVSI 3.619 1.312–9.983 0.013 3.324 1.190–9.282 0.022
 Number of positive LN’s 1.134 1.041–1.235 0.004 1.192 1.077–1.318 0.001
 ER- positive 0.344 0.119–0.992 0.048 0.159 0.050–0.508 0.002
Any recurrence
 LVSI 2.616 1.252–5.464 0.011 2.452 1.165–5.160 0.018
 Downstaged 0.268 0.108–0.665 0.005 0.340 0.128–0.907 0.031
 African- American race 2.383 1.143–4.970 0.021
 Positive family history 0.428 0.183–1.004 0.051
 Number of positive LN’s 1.098 1.017–1.187 0.018
Locoregional recurrence
 African- American Race 3.479 1.103–10.973 0.033 4.270 1.279–14.250 0.018
 LVSI 3.821 1.113–13.122 0.033 4.283 1.141–16.072 0.031
 Number of Positive LN’s 1.194 1.090–1.307 <0.001 1.203 1.093–1.325 <0.001
 Downstaged 0.179 0.034–0.938 0.042
Distant metastasis
 LVSI 2.525 1.210–5.268 0.014 2.441 1.161–5.131 0.019
 Downstaged 0.285 0.116–0.704 0.006 0.340 0.128–0.907 0.031
 African- American race 2.374 1.138–4.951 0.021
 Positive family history 0.424 0.181–0.994 0.048
 Number of positive LN’s 1.095 1.015–1.181 0.019
TN, triple negative; ALND, axillary lymph node dissection; LVSI, lymphovascular space invasion; LN, lymph nodes; ER, estrogen receptor; HR, hazard 
ratio (HR > 1 represents increased likelihood of having event).
Table 5. Impact of LVSI on outcomes.
Survival 2 years (%) 4 years (%) P- value
Overall survival 95 84 0.009
 With LVSI 91 70
 Without LVSI 96 92
Recurrence- free survival (RFS) 86 71 0.010
 With LVSI 80 52
 Without LVSI 88 82
Locoregional RFS 95 87 0.022
 With LVSI 91 73
 Without LVSI 97 95
Distant metastasis- free survival 87 72 0.010
 With LVSI 86 54
 Without LVSI 88 82
P- values calculated using Log- rank (Mantel- Cox). LVSI, lymphovascular 
space invasion.
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the understanding that young women tend to present 
with more advanced disease, our goal in limiting this 
study to age less than 40 with LABC was to remove age 
as a variable and focus solely on those patients who 
 presented with locally advanced disease.
In presenting a pooled analysis of four European 
Organization for Research and Treatment of Cancer 
(EORTC) clinical trials, van der Hage et al. reveal  tumor 
size, nodal status, and molecular subtype as independ-
ent prognostic factors for OS in young women with 
breast cancer, with only molecular subtype as a prog-
nostic factor for OS in the node negative group [19]. 
In our study of predominantly node positive  patients, 
TN status and presence of LVSI were shown on 
multivariate analysis to be predictive of OS. Number 
of positive lymph nodes also correlated with worse OS. 
Patients presenting with LVSI had an absolute decrease 
in survival at 4 years of over 20%. Type of surgery 
(breast conserving therapy [BCT] vs mastectomy) in 
this young age group did not affect any of the outcomes 
measured. This is consistent with a recently published 
meta- analysis summarizing 6 studies comparing OS 
between patients receiving BCT vs mastectomy in  patients 
less than 40 years [20].
In terms of LRR- free survival, distant- metastasis free- 
survival and RFS, presence of LVSI was again highlighted 
as a variable significant on multivariate analysis. Our data 
demonstrate a DM- free survival of only 54% at 4 years 
Figure 1. Overall survival and recurrence- free survival (RFS). Kaplan–Meier survival plots of (A) overall survival (OS) with and without lymphovascular 
space invasion (LVSI), (B) RFS with and without LVSI, (C) OS in patients receiving neoadjuvant chemotherapy stratified by downstaging, (D) RFS in 
patients receiving neoadjuvant chemotherapy stratified by downstaging. P- values represent results of log- rank analysis.
A B
C D
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in young women presenting with LVSI. In a recent study 
of early stage breast cancer, Freedman et al. studied the 
prognostic importance of LVSI after conservative surgery 
and radiation [21]. Although 5- and 10- year locoregional 
RFS and OS were decreased for patients with LVSI in 
their cohort of patients with a median age around 55, 
LVSI was not found to be an independent predictor of 
local/regional failure or decreased survival on multivariate 
analysis. In our cohort of LABC, young women with 
LVSI were more likely to recur, having a RFS at four 
years of approximately 52% compared to 82% for young 
women without evidence of LVSI. Huang et al. investi-
gated predictors of LRR in patients with a median age 
of 50 with LABC treated with neoadjuvant chemotherapy, 
mastectomy, and radiotherapy, revealing factors on mul-
tivariate analysis that independently predicted for LRR: 
skin/nipple involvement, supraclavicular disease, extraca-
psular extension, and estrogen- receptor negative disease 
[22]. Our series reveals a number of positive LN’s, African 
American race, and presence of LVSI as significant fac-
tors for LRR.
There have been significant efforts to elucidate an un-
derlying biological explanation as to why young women 
have a more aggressive course compared to elderly women. 
Recent gene expression profiling studies have showed that 
young women have a higher probability of PI3K, Myc, 
and B- catenin deregulation and lower mRNA levels of 
ER and progesterone receptor, but higher levels of HER2 
and epidermal growth factor receptor [23]. Azim et al. 
evaluated whether previously published proliferation, 
stroma, and immune- related gene signatures were predic-
tive of prognosis in young women [24]. Their analyses 
suggested that breast cancer in young women is enriched 
with processes related to mammary stem cells (e.g., RANKL, 
c- kit, luminal progenitors) and growth factor signaling. 
These studies and others like it have successfully identified 
certain signaling pathways and gene expression signatures 
associated with breast cancer in young women, suggesting 
that breast cancer in young women is a unique disease 
entity compared to breast cancer arising in the older 
population.
It is becoming clear that achieving a pathologic complete 
response (pCR) prior to surgery improves disease- free 
survival [25]. Loibl and colleagues of the German Breast 
Group presented results of a German meta- analysis at 
the 2012 San Antonio Breast Cancer Symposium. 
Interestingly, they found that the pathologic complete 
response was higher in young women compared to older 
women (23% vs. 13.5%). Furthermore, young women who 
did not achieve a pCR had inferior disease- free and local 
RFS compared to those women that achieved pCR. In 
our series, patients with TN disease were more likely to 
achieve a pCR compared to non- TN patients (P = 0.04), 
consistent with a study from MD Anderson [26]. Cortazar 
and colleagues in a recent Lancet article showed that pa-
tients with pCR had improved survival, but the utility of 
pCR as a surrogate endpoint for survival was not validated 
[27]. A recent meta- analysis of 29 neoadjuvant trials reached 
the conclusion that use of pCR as a surrogate for out-
comes is not justified [28]. Regardless of the utility in 
using pCR to predict outcomes, the unique biology of 
breast cancer in young women may render their tumors 
more responsive to neoadjuvant treatment. In our cohort 
of young women with LABC, 12 patients (19.4%) achieved 
a pCR and 38 patients (61.3%) were downstaged, which 
was a statistically significant factor for DM- free survival 
and RFS. However, the high rate of pCR/downstaging 
may be related to the high proportion of triple negative 
patients in this series. Moreover, downstaging after neo-
adjuvant chemotherapy was associated with RFS but not 
OS, likely due to short follow- up and salvage therapy in 
ER+ patients.
There are inherent limitations associated with a single 
institution retrospective analysis. It is understood that 
treatment regimens at institutions can vary significantly. 
It should be emphasized that this series only included 
patients that had radiotherapy as a required component 
of management. However, LABC in young women is 
 invariably treated with some combination of surgery, 
 radiation, and chemotherapy.
This study highlights two already known and established 
poor prognostic indicators, namely LVSI and poor response 
to neoadjuvant chemotherapy, in the overall management 
of these young women. Given an inferior prognosis com-
pared to older women and evidence of a biologically 
distinct entity, there appears to be a need for clinical 
trials geared specifically to young women with breast 
cancer. Prospectively designed collaborations to specifically 
investigate novel therapeutic approaches in young women 
with breast cancer are required.
Conflict of Interest
The authors declare no conflicts of interest.
References
 1.  SEER Stat Fact Sheets: Breast Cancer. Available at seer.
cancer.gov/statfacts/html/breast.html (accessed 05 June 
2015).
 2.  Anders, C. K., R. Johnson, J. Litton, M. Phillips, and A. 
Bleyer. 2009. Breast cancer before age 40 years. Semin. 
Oncol. 36:237–249. doi:10.1053/j.seminoncol.2009.03.001
 3.  Beadle, B. M., W. A. Woodward, and T. A. Buchholz. 
2011. The impact of age on outcome in early- stage 
breast cancer. Semin. Radiat. Oncol. 21:26–34. 
doi:10.1016/j.semradonc.2010.09.001
237© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Breast Cancer in Young WomenS. S. Khwaja et al.
 4.  Giordano, S. H. 2003. Update on locally advanced 
breast cancer. Oncologist 8:521–530. doi:10.1634/
theoncologist.8- 6- 521
 5.  Maggard, M. A., J. B. O’Connell, K. E. Lane, J. H. Liu, 
D. A. Etzioni, and C. Y. Ko. 2003. Do young breast 
cancer patients have worse outcomes? J. Surg. Res. 
113:109–113.
 6.  Vollmer, R. T. 1996. Younger women with breast 
carcinoma have a poorer prognosis than older women. 
Cancer 78:1518–1519.
 7.  Anders, C. K., D. S. Hsu, G. Broadwater, C. R. 
Acharya, J. A. Foekens, Y. Zhang, et al. 2008. Young 
age at diagnosis correlates with worse prognosis and 
defines a subset of breast cancers with shared patterns 
of gene expression. J. Clin. Oncol. 26:3324–3330. 
doi:10.1200/JCO.2007.14.2471
 8.  Bharat, A., R. L. Aft, F. Gao, and J. A. Margenthaler. 
2009. Patient and tumor characteristics associated with 
increased mortality in young women (≤40 years) with 
breast cancer. J. Surg. Oncol. 100:248–251. doi:10.1002/
jso.21268
 9.  Goldhirsch, A., R. D. Gelber, G. Yothers, R. J. Gray, S. 
Green, J. Bryant, et al. 2001. Adjuvant therapy for very 
young women with breast cancer: need for tailored 
treatments. J. Natl. Cancer Inst. Monogr. 30:44–51.
10.  Goddu, S. M., S. Chaudhari, M. Mamalui-Hunter, O. L. 
Pechenaya, D. Pratt, S. Mutic, et al. 2009. Helical 
tomotherapy planning for left- sided breast cancer 
patients with positive lymph nodes: comparison to 
conventional multiport breast technique. Int. J. Radiat. 
Oncol. Biol. Phys. 73:1243–1251. doi:10.1016/j.
ijrobp.2008.11.004
11.  Copson, E., B. Eccles, T. Maishman, et al. 2013. 
Prospective observational study of breast cancer 
treatment outcomes for UK women aged 18–40 years at 
diagnosis: the POSH study. J. Natl Cancer Inst. 105: 
978–988. doi:10.1093/jnci/djt134
12.  Beadle, B. M., W. A. Woodward, S. L. Tucker, E. D. 
Outlaw, P. K. Allen, J. L. Oh, et al. 2009. Ten- year 
recurrence rates in young women with breast cancer by 
locoregional treatment approach. Int. J. Radiat. Oncol. 
Biol. Phys. 73:734–744. doi:10.1016/j.ijrobp.2008.04.078
13.  Fowble, B. L., D. J. Schultz, B. Overmoyer, L. J. Solin, 
K. Fox, L. Jardines, et al. 1994. The influence of young 
age on outcome in early stage breast cancer. Int. J. 
Radiat. Oncol. Biol. Phys. 30:23–33.
14.  McAree, B., M. E. O’Donnell, A. Spence, T. F. Lioe, D. 
T. McManus, and R. A. J. Spence. 2010. Breast cancer 
in women under 40 years of age: a series of 57 cases 
from Northern Ireland. Breast Edinb. Scotl. 19:97–104. 
doi:10.1016/j.breast.2009.12.002
15.  Tavani, A., S. Gallus, C. La Vecchia, E. Negri, M. 
Montella, L. Dal Maso, et al. 1999. Risk factors for 
breast cancer in women under 40 years. Eur. J. Cancer 
Oxf. Engl. 35:1361–1367.
16.  Tehranian, N., F. Shobeiri, F. H. Pour, and E. 
Hagizadeh. 2010. Risk factors for breast cancer in 
Iranian women aged less than 40 years. Asian Pac. J. 
Cancer Prev. APJCP 11:1723–1725.
17.  Zhou, P., and A. Recht. 2004. Young age and outcome 
for women with early- stage invasive breast carcinoma. 
Cancer 101:1264–1274. doi:10.1002/cncr.20523
18.  Gnerlich, J. L., A. D. Deshpande, D. B. Jeffe, A. Sweet, 
N. White, and J. A. Margenthaler. 2009. Elevated breast 
cancer mortality in women younger than age 40 years 
compared with older women is attributed to poorer 
survival in early- stage disease. J. Am. Coll. Surg. 
208:341–347. doi:10.1016/j.jamcollsurg.2008.12.001
19.  Van der Hage, J. A., J. S. D. Mieog, C. J. H. van de 
Velde, H. Putter, H. Bartelink, and M. J. van de Vijver. 
2011. Impact of established prognostic factors and 
molecular subtype in very young breast cancer patients: 
pooled analysis of four EORTC randomized controlled 
trials. Breast Cancer Res. BCR 13:R68. doi:10.1186/
bcr2908
20.  Vila, J., S. Gandini, and O. Gentilini. 2015. Overall 
survival according to type of surgery in young 
(≤40 years) early breast cancer patients: a systematic 
meta- analysis comparing breast- conserving surgery versus 
mastectomy. Breast Edinb. Scotl. 24:175–181. 
doi:10.1016/j.breast.2015.02.002
21.  Freedman, G. M., T. Li, L. V. Polli, P. R. Anderson, 
R. J. Bleicher, E. Sigurdson, et al. 2012. Lymphatic 
space invasion is not an independent predictor of 
outcomes in early stage breast cancer treated by 
breast- conserving surgery and radiation. Breast J. 
18:415–419. doi:10.1111/j.1524- 4741.2012.01271.x
22.  Huang, E. H., S. L. Tucker, E. A. Strom, M. D. 
McNeese, H. M. Kuerer, G. N. Hortobagyi, et al. 2005. 
Predictors of locoregional recurrence in patients with 
locally advanced breast cancer treated with neoadjuvant 
chemotherapy, mastectomy, and radiotherapy. Int. J. 
Radiat. Oncol. Biol. Phys. 62:351–357. doi:10.1016/j.
ijrobp.2004.09.056
23.  Anders, C. K., C. R. Acharya, D. S. Hsu, G. 
Broadwater, K. Garman, J. A. Foekens, et al. 2008. 
Age- specific differences in oncogenic pathway 
deregulation seen in human breast tumors. PLoS ONE 
3:e1373. doi:10.1371/journal.pone.0001373
24.  Azim, H. A. Jr, S. Michiels, P. L. Bedard, S. K. 
Singhal, C. Criscitiello, M. Ignatiadis, et al. 2012. 
Elucidating prognosis and biology of breast cancer 
arising in young women using gene expression 
profiling. Clin. Cancer Res. Off. J. Am. Assoc. Cancer 
Res. 18:1341–1351. doi:10.1158/1078- 0432.
CCR- 11- 2599
238 © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
S. S. Khwaja et al.Breast Cancer in Young Women
25.  Von Minckwitz, G., M. Untch, J.-U. Blohmer, S. D. 
Costa, H. Eidtmann, P. A. Fasching, et al. 2012. 
Definition and impact of pathologic complete response 
on prognosis after neoadjuvant chemotherapy in various 
intrinsic breast cancer subtypes. J. Clin. Oncol. Off. J. 
Am. Soc. Clin. Oncol. 30:1796–1804. doi:10.1200/
JCO.2011.38.8595
26.  Liedtke, C., C. Mazouni, K. R. Hess, F. André, 
A. Tordai, J. A. Mejia, et al. 2008. Response to 
neoadjuvant therapy and long- term survival in patients 
with triple- negative breast cancer. J. Clin. Oncol. Off. J. 
Am. Soc. Clin. Oncol. 26:1275–1281. doi:10.1200/
JCO.2007.14.4147
27.  Cortazar, P., L. Zhang, M. Untch, K. Mehta, J. P. 
Costantino, N. Wolmark, et al. 2014. Pathological 
complete response and long- term clinical benefit in 
breast cancer: the CTNeoBC pooled analysis. Lancet 
384:164–172. doi:10.1016/S0140- 6736(13)62422- 8
28.  Berruti, A., V. Amoroso, F. Gallo, V. Bertaglia, E. 
Simoncini, R. Pedersini, et al. 2014. Pathologic complete 
response as a potential surrogate for the clinical 
outcome in patients with breast cancer after 
neoadjuvant therapy: a meta- regression of 29 
randomized prospective studies. J. Clin. Oncol. Off. J. 
Am. Soc. Clin. Oncol. 32:3883–3891. doi:10.1200/
JCO.2014.55.2836
